Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Recs

0
Player Avatar sheltie101 (< 20) Submitted: 7/10/2009 10:42:05 PM : Outperform Start Price: $8.11 CRTX Score: -82.42

Asthma as a health problem is increasing and CRTX has solid offerings for treatment.

Featured Broker Partners


Advertisement